Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Exudative Age-Related Macular Degeneration: early-phase trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Exudative Age-Related Macular Degeneration: 3 US clinical trials tracked, none currently recruiting.
Exudative Age-Related Macular Degeneration is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Lpath, running 1 of these trials.
Enrollment posture brief
Registry condition exudative-age-related-macular-degeneration
OPEN 0 | RECR 0% | LATE 0 | EARLY 2 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Exudative Age-Related Macular Degeneration has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Exudative Age-Related Macular Degeneration on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Exudative Age-Related Macular Degeneration is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD
Lpath
NCT01414153
Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration
Stanford University
NCT01526070
Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration
Alcon Research
NCT01157065
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Exudative Age-Related Macular Degeneration records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Exudative Age-Related Macular Degeneration trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Exudative Age-Related Macular Degeneration page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Exudative Age-Related Macular Degeneration trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Lpath sponsors the most Exudative Age-Related Macular Degeneration trials on record, review their full trial history before evaluating a specific study. See Lpath's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Exudative Age-Related Macular Degeneration condition card totals 3 registered trials; most-linked intervention sham injection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.